Ventyx Biosciences Engages in Key Investor Conferences
Ventyx Biosciences, Inc. (Nasdaq: VTYX) is a clinical-stage biopharmaceutical company committed to developing innovative oral therapies aimed at addressing significant unmet medical needs in inflammatory diseases. The company has announced that its executives will be participating in several key investor conferences in the coming weeks.
Upcoming Investor Conferences
The first major event is the 2024 Wells Fargo Healthcare Conference, where Ventyx will provide insights into its operations. This conference is set for September 4, with the presentation scheduled from 11:00 to 11:35 AM ET. Investors and interested parties are encouraged to tune in to gain a better understanding of Ventyx's strategic direction.
Wells Fargo Healthcare Conference Details
Event: 2024 Wells Fargo Healthcare Conference
Time: 11:00 - 11:35 AM ET
Morgan Stanley Global Healthcare Conference
After the Wells Fargo Conference, Ventyx will also take part in the Morgan Stanley 22nd Annual Global Healthcare Conference. This event is crucial for stakeholders who want to understand the company's position in the healthcare market and will be held on September 6 from 1:05 to 1:40 PM ET. These presentations will be essential for informing investors about Ventyx's future plans and financial health.
Morgan Stanley Conference Details
Event: Morgan Stanley 22nd Annual Global Healthcare Conference
Time: 1:05 - 1:40 PM ET
Webcast Availability
Ventyx Biosciences will offer a live webcast of the presentations from both conferences, allowing investors who cannot attend in person to engage with the content. Interested individuals can find the webcast in the Investors and News section on Ventyx's official website. Additionally, a replay of each session will be accessible for thirty days following the events, ensuring that all interested parties can access the vital information shared.
About Ventyx Biosciences
Ventyx Biosciences is dedicated to pioneering novel oral therapies for the treatment of inflammatory diseases. The company is focused on efficiently discovering and developing unique drug candidates to facilitate the transition from injectable to oral medications in this therapeutic area. Their current pipeline includes programs targeting NLRP3, S1P1R, and TYK2, positioning Ventyx at the forefront of innovations in oral therapies for both peripheral and neuroinflammatory conditions.
Investor Relations
For more information regarding Ventyx's mission, product pipeline, and corporate strategies, investors are encouraged to reach out directly. Patti Bank, Managing Director at ICR Westwicke, is the contact for investor relations and can be reached at (415) 513-1284 or via email at IR@ventyxbio.com.
Frequently Asked Questions
What is Ventyx Biosciences known for?
Ventyx Biosciences is known for developing innovative oral therapies aimed at treating inflammatory diseases that have significant unmet medical needs.
When are the upcoming investor conferences?
The Wells Fargo Healthcare Conference is scheduled for September 4, while the Morgan Stanley Global Healthcare Conference will take place on September 6.
How can investors access the presentations?
Investors can view a live webcast of the presentations on Ventyx’s website, with replays available for thirty days after each event.
Who can investors contact for more information?
For inquiries, investors can contact Patti Bank, Managing Director at ICR Westwicke, at (415) 513-1284 or via email at IR@ventyxbio.com.
What therapeutic areas does Ventyx concentrate on?
Ventyx specializes in oral therapies targeting inflammatory conditions, with a particular focus on peripheral and neuroinflammatory diseases.
